RT Journal Article
T1 Metformin: A hopeful promise in aging research
A1 Garrido Novelle, Marta
A1 Ali, Ahmed
A1 Diéguez, Carlos
A1 Bernier, Michel
A1 De Cabo, Rafael
AB Even though the inevitable process of aging by itself cannot be considered a disease, it is directly linked to life span and is the driving force behind all age-related diseases. It is an undisputable fact that age-associated diseases are among the leading causes of death in the world, primarily in industrialized countries. During the last several years, an intensive search of antiaging treatments has led to the discovery of a variety of drugs that promote health span and/or life extension. The biguanide compound metformin is widely used for treating people with type 2 diabetes and appears to show protection against cancer, inflammation, and age-related pathologies. Here, we summarize the recent developments about metformin use in translational aging research and discuss its role as a potential geroprotector.
PB Cold Spring Harbor Laboratory Press
YR 2016
FD 2016
LK https://hdl.handle.net/20.500.14352/94831
UL https://hdl.handle.net/20.500.14352/94831
LA eng
NO Novelle, Marta G., et al. «Metformin: A Hopeful Promise in Aging Research». Cold Spring Harbor Perspectives in Medicine, vol. 6, n.o 3, marzo de 2016, p. a025932. https://doi.org/10.1101/cshperspect.a025932.
NO This work is supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. CIBER de Fisiopatología de la Obesidad y Nutrición is an initiative of ISCIII. The funding agency had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
NO National Institutes of Health
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 4 abr 2025